Clinical Trial Update: Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 trial of IMO-3100 in moderate to severe plaque psoriasis completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis
• Psoriasis Plaque

Drugs mentioned

• IMO-3100

Snippet

Sponsor: Idera Pharmaceuticals, Inc. | Conditions: Actively Extending Plaque Psoriasis, Moderate to Severe Plaque Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2017-11-13